Reckitt Benckiser agrees to pay $30 million to settle end payors' claims in US Suboxone antitrust case
MLex Summary: Reckitt Benckiser agreed to a $30 million settlement with end-payor plaintiffs accusing it of conspiring to block generic competition for the drug Suboxone. The deal is subject to US...To view the full article, register now.
Already a subscriber? Click here to view full article